13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
Key Takeaways
- Chemotherapy extravasation requires immediate differentiation into vesicants (DNA-binding [anthracyclines, mitomycin-C] causing progressive deep tissue necrosis vs. non-DNA binding [vinca alkaloids, taxanes] causing local diffuse injury), irritants, and non-vesicants to direct immediate thermal and antidotal interventions.
- Thermal management is drug-class specific: DNA-binding vesicants (anthracyclines, mitomycin) and cisplatin require COLD packs (vasoconstriction to localize drug), whereas vinca alkaloids (vincristine, vinblastine) and epipodophyllotoxins (etoposide) mandate DRY WARM HEAT packs (vasodilation to disperse drug and enhance enzymatic clearance).
- Dexrazoxane (Totect/Savene) is the FDA-approved systemic antidote for anthracycline extravasation, administered as a 3-day IV infusion (1000 mg/m2 Day 1, 1000 mg/m2 Day 2, 500 mg/m2 Day 3; 50% dose reduction if CrCl <50 mL/min) initiated within 6 hours into a separate vein, with cold packs removed >=15 minutes prior to infusion.
- Mesna (sodium 2-mercaptoethanesulfonate) is mandatory with all doses of ifosfamide and high-dose cyclophosphamide (>=1500–2000 mg/m2) to prevent acrolein-induced hemorrhagic cystitis by donating free sulfhydryl groups in the urinary bladder to form a stable, non-toxic thioether; mesna does not impair antineoplastic systemic efficacy.
- Glucarpidase (Voraxaze, carboxypeptidase G2) is indicated for toxic methotrexate concentrations in the setting of acute kidney injury; it rapidly hydrolyzes MTX into inactive DAMPA within 15 minutes, but because DAMPA cross-reacts on commercial immunoassay MTX tests, leucovorin rescue must NOT be administered within 2 hours before or after glucarpidase and should continue based on pre-glucarpidase MTX concentrations.
Last updated: August 2026
13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
Antineoplastic extravasation and off-target organ toxicities represent critical areas of clinical oncology pharmacy oversight. Extravasation—the accidental infiltration of a cytotoxic agent into surrounding perivascular or subcutaneous tissues—can result in devastating complications, including severe pain, progressive full-thickness tissue necrosis, tendon and nerve destruction, joint contractures, compartment syndrome, and permanent loss of extremity function.
Simultaneously, specific high-dose chemotherapy regimens generate organ-specific toxic metabolites that necessitate co-administered cytoprotective protectants (e.g., mesna for oxazaphosphorine-induced hemorrhagic cystitis, leucovorin for methotrexate-induced intracellular folate depletion) or emergency toxicologic antidotes (e.g., glucarpidase for methotrexate-induced renal failure, uridine triacetate for fluoropyrimidine overdose).
1. Chemotherapy Extravasation: Classification & Pathophysiology
+---------------------------------------------------------------------------------------------------+
| CYTOTOXIC EXTRAVASATION CLASSIFICATION SPECTRUM |
| |
| [VESICANTS: DNA-BINDING] (Highest Hazard - Progressive Severe Necrosis) |
| - **Anthracyclines:** Doxorubicin, Daunorubicin, Epirubicin, Idarubicin |
| - **Antitumor Antibiotics:** Mitomycin-C, Dactinomycin (Actinomycin D) |
| - *Mechanism:* Extravasated drug enters local tissue cells, intercalates into DNA, and causes |
| cell death. Dead cells lyse and release the intact, active drug back into the extracellular |
| space, where it is endocytosed by adjacent healthy cells ==> Self-perpetuating, progressive, |
| expanding ischemic necrosis that deepens over weeks and requires wide surgical excision! |
| |
| [VESICANTS: NON-DNA-BINDING] (High Hazard - Diffuse Blistering / Ulceration) |
| - **Vinca Alkaloids:** Vincristine, Vinblastine, Vinorelbine |
| - **Taxanes:** Paclitaxel, Docetaxel, Cabazitaxel |
| - **Others:** Trabectedin |
| - *Mechanism:* Binds tubulin / microtubules; does not bind DNA. Causes acute cellular injury, |
| severe blistering, and desquamation, but drug is gradually cleared and metabolized locally. |
| |
| [IRRITANTS WITH VESICANT POTENTIAL AT HIGH CONCENTRATIONS / VOLUMES] |
| - Cisplatin (> 20 mL of > 0.4 mg/mL concentration) |
| - Carboplatin, Oxaliplatin |
| - Dacarbazine, Carmustine (BCNU), Ifosfamide, Fluorouracil, Topotecan |
| - *Mechanism:* Causes aching, burning, phlebitis, and erythema along the vein, but rarely |
| progresses to tissue necrosis unless very large volumes or high concentrations extravasate. |
| |
| [NON-VESICANTS / NON-IRRITANTS] |
| - Monoclonal Antibodies, Bleomycin, Methotrexate, Cytarabine, Gemcitabine, Cyclophosphamide |
+---------------------------------------------------------------------------------------------------+
Clinical Distinction: Extravasation vs. Anthracycline "Flare Reaction"
- Anthracycline Flare Reaction: A benign, histamine-mediated local vascular flare occurring in up to 3% of patients receiving IV doxorubicin/epirubicin. Characterized by erythematous, painless streaks tracking along the vein, urticaria, and pruritus WITHOUT pain, swelling, induration, or extravasation. Management: Slow the infusion rate, flush with normal saline, consider oral/IV diphenhydramine; resolves spontaneously within 30–60 minutes without tissue injury.
- True Anthracycline Extravasation: Immediate severe burning pain, stinging, induration, significant swelling, lack of blood return from the cannula. Progresses to erythema, blistering, ulceration, and necrosis.
2. Immediate Step-by-Step Extravasation Management Protocol
+---------------------------------------------------------------------------------------------------+
| UNIVERSAL EXTRAVASATION INTERVENTION PROTOCOL |
| |
| 1. **STOP THE INFUSION IMMEDIATELY!** |
| 2. **DO NOT REMOVE THE INTRAVENOUS CANNULA / NEEDLE!** |
| 3. Disconnect IV infusion tubing from the cannula. |
| 4. Attach a small syringe (3-5 mL) to the cannula and **gently aspirate 3 to 5 mL of blood / |
| extravasated drug solution** to remove residual drug from the subcutaneous space. |
| 5. If a local antidote requires subcutaneous infiltration (e.g., Hyaluronidase, Sodium |
| Thiosulfate), administer it through the existing cannula, THEN remove the cannula. |
| 6. Outline the extravasation boundary with an indelible skin marker for ongoing serial exams. |
| 7. Elevate the affected limb above the level of the heart for 48 hours to promote lymphatic |
| drainage and reduce dependent edema. |
| 8. Apply the appropriate **THERMAL COMPRESS** (Cold vs. Warm) based on the drug class! |
| 9. Administer specific systemic or topical antidotes (Dexrazoxane, DMSO, Hyaluronidase). |
| 10. Consult Surgical / Plastic Surgery if extensive extravasation, persistent ulceration, or |
| severe necrosis develops. |
+---------------------------------------------------------------------------------------------------+
Master Extravasation Thermal & Antidote Matrix
| Chemotherapy Class / Specific Drug | Thermal Management (Compress Type & Timing) | Specific Antidote & Administration Protocol | Pharmacologic Mechanism of Antidote |
|---|---|---|---|
| Anthracyclines<br>(Doxorubicin, Daunorubicin, Epirubicin, Idarubicin) | DRY COLD PACKS<br>(Apply for 15–20 min QID for 24–48h).<br>Mandate: Remove cold pack >=15 min prior to Dexrazoxane! | DEXRAZOXANE (Totect / Savene) - PREFERRED:<br>3-Day IV Infusion (into a separate vein!):<br>• Day 1: 1,000 mg/m2 (max 2,000 mg)<br>• Day 2: 1,000 mg/m2 (max 2,000 mg)<br>• Day 3: 500 mg/m2 (max 1,000 mg)<br>(Initiate within 6 hours! Reduce dose by 50% if CrCl <50 mL/min).<br>DMSO 99% (Topical) - Alternative:<br>Apply 4 drops/10 cm2 to skin Q8H for 7–14 days. | Dexrazoxane: Catalytic Topoisomerase II inhibitor; prevents anthracycline-mediated DNA damage and iron-dependent free-radical tissue necrosis.<br>DMSO: Free-radical scavenger and penetration enhancer. |
| Vinca Alkaloids<br>(Vincristine, Vinblastine, Vinorelbine) | DRY WARM HEAT PACKS<br>(Apply for 15–20 min QID for 24–48h).<br>Cold is CONTRAINDICATED (increases vinca ulceration!) | HYALURONIDASE:<br>Dose: 150 to 1,500 units (1–2 mL of 150 units/mL).<br>Administer as 4–5 divided subcutaneous injections (0.2 mL each) in a clockwise circle around the periphery of the extravasation site. | Enzymatically hydrolyzes hyaluronic acid in the extracellular matrix, promoting rapid tissue dispersion and systemic absorption/dilution. |
| Taxanes<br>(Paclitaxel, Docetaxel, Cabazitaxel) | DRY WARM HEAT PACKS (or Cold in select guidelines) | HYALURONIDASE:<br>Dose: 150 to 1,500 units SC around extravasation site. | Promotes tissue dispersion and systemic dilution of non-DNA binding taxane molecules. |
| Mechlorethamine<br>(Nitrogen Mustard) | DRY COLD PACKS | SODIUM THIOSULFATE (1/6 Molar = ~10%):<br>Inject 2 mL SC into extravasation site for each 1 mg mechlorethamine extravasated. | Provides excess nucleophilic thiosulfate ions that rapidly inactivate highly reactive alkylating aziridinium ions. |
| Cisplatin<br>(Extravasation >20 mL of >0.4 mg/mL) | DRY COLD PACKS | SODIUM THIOSULFATE (1/6 Molar):<br>Inject 2 to 4 mL SC for large-volume concentrated extravasations. | Inactivates platinum reactive intermediates and prevents local tissue necrosis. |
| Etoposide / Teniposide | DRY WARM HEAT PACKS | HYALURONIDASE: 150 to 1,500 units SC around margin. | Promotes rapid tissue dispersion and lymphatic clearance. |
3. Cytoprotective Organ Protectants & Toxicologic Antidotes
+---------------------------------------------------------------------------------------------------+
| ORGAN PROTECTANTS & ANTIDOTES MASTER SUMMARY |
| |
| [DEXRAZOXANE (Zinecard)] ==> Anthracycline Cardioprotection |
| [MESNA (Mesnex)] ========> Oxazaphosphorine (Ifosfamide/Cyclo) Uroprotection |
| [LEUCOVORIN (Folinic)] == > High-Dose Methotrexate Rescuing |
| [GLUCARPIDASE (Voraxaze)] > Methotrexate-Induced Acute Renal Failure |
| [AMIFOSTINE (Ethyol)] === > Cisplatin Nephrotoxicity / Radiation Xerostomia |
| [URIDINE TRIACETATE] === > 5-FU / Capecitabine Overdose or DPYD Early Toxicity |
| [METHYLENE BLUE] ======= > Ifosfamide-Induced Encephalopathy |
+---------------------------------------------------------------------------------------------------+
1. Dexrazoxane for Anthracycline-Induced Cardiotoxicity (Zinecard)
Anthracyclines (doxorubicin, epirubicin) form complexes with intracellular iron, generating toxic hydroxyl free radicals that induce myocyte lipid peroxidation, mitochondrial damage, myofibrillar loss, and irreversible cardiomyopathy.
- Indication: Prevention of cardiomyopathy in patients with metastatic breast cancer or advanced solid tumors who have received a cumulative Doxorubicin dose >= 300 mg/m2 (or Epirubicin >= 540 mg/m2) and who continue to benefit from anthracycline therapy.
- Dosing & Administration: Administer at a 10:1 dose ratio of Dexrazoxane to Doxorubicin (e.g., 500 mg/m2 Dexrazoxane for every 50 mg/m2 Doxorubicin). Administered as a 15-minute IV infusion completed within 30 minutes PRIOR to doxorubicin administration.
2. Mesna (Sodium 2-Mercaptoethanesulfonate) for Oxazaphosphorine Urotoxicity
- Pathophysiology: Hepatic CYP450 metabolism of Ifosfamide and Cyclophosphamide produces Acrolein, an unsaturated, highly reactive aldehyde metabolite. Acrolein concentrates in the bladder, binding to urothelial proteins, causing severe ulceration, edema, microvascular neovascularization, and life-threatening Hemorrhagic Cystitis.
- Mesna Mechanism: Mesna is rapidly oxidized in circulation to dimesna, filtered by the glomerulus, and reduced back to free mesna in the renal tubules. The free sulfhydryl (-SH) group of mesna binds directly to the double bond of acrolein, creating a stable, non-toxic thioether conjugate excreted in the urine.
- Dosing Protocols:
- Ifosfamide: Mesna is MANDATORY for ALL doses of Ifosfamide. Mesna total daily dose equals 60% to 100% of the daily Ifosfamide dose.
- Standard IV Push Regimen: Mesna 20% of ifosfamide dose IV at Hour 0 (with ifosfamide), Hour 4, and Hour 8 (total 60%).
- Continuous IV Infusion: Mesna 20% IV bolus at Hour 0, then continuous infusion of 100% of ifosfamide dose over 24 hours.
- Cyclophosphamide: Mesna is not routinely required for standard doses (<1500 mg/m2; managed with vigorous hydration). Mesna is MANDATORY in high-dose cyclophosphamide (>=1500–2000 mg/m2) used in HSCT conditioning.
- Ifosfamide: Mesna is MANDATORY for ALL doses of Ifosfamide. Mesna total daily dose equals 60% to 100% of the daily Ifosfamide dose.
3. Leucovorin & Glucarpidase for High-Dose Methotrexate (HD-MTX)
High-Dose Methotrexate (>=500 mg/m2 up to 12 g/m2) competitively inhibits Dihydrofolate Reductase (DHFR), depleting intracellular reduced folates (THF), halting purine/pyrimidine synthesis.
+---------------------------------------------------------------------------------------------------+
| HD-MTX SAFETY & RESCUE PROTOCOL MATRIX |
| |
| 1. HYPERHYDRATION & URINARY ALKALINIZATION (PREVENTION OF PRECIPITATION): |
| - Hydration: IV fluids at 150-200 mL/hr with Sodium Bicarbonate (40-50 mEq/L). |
| - Mandatory Threshold: Maintain **Urine pH >= 7.5** and urine output **>= 100 mL/hr**. |
| - *Clinical Rationale:* MTX and its 7-OH-MTX metabolite precipitate in acidic urine |
| (solubility increases by >10-fold at pH >=7.5 vs pH 5.5). |
| |
| 2. LEUCOVORIN (Folinic Acid) RESCUE: |
| - Mechanism: Formyl derivative of THF; directly provides active reduced folate cofactors, |
| **bypassing DHFR inhibition** to rescue normal bone marrow and gastrointestinal cells. |
| - Timing: Initiated at **24 to 36 hours** after the START of the MTX infusion. |
| - Dosing: Standard: 15-25 mg PO/IV every 6 hours; escalated up to 100-1000 mg/m2 Q3H for |
| delayed clearance based on MTX nomograms, until **serum MTX level < 0.05 to 0.1 mcmol/L**. |
| |
| 3. GLUCARPIDASE (Voraxaze - Carboxypeptidase G2): |
| - Indication: **Toxic MTX concentrations in patients with MTX-induced Acute Kidney Injury** |
| (delayed MTX clearance >2 standard deviations above nomogram with SCr elevation). |
| - Mechanism: Recombinant bacterial enzyme that rapidly hydrolyzes extracellular MTX into |
| inactive metabolites: **DAMPA** (4-[[2,4-diamino-6-pteridinyl)methyl]amino]benzoic acid) |
| and glutamate, reducing plasma MTX by **> 95% within 15 minutes**! |
| - Dose: **50 units/kg IV push over 5 minutes**. |
| - PHARMACY MANDATE 1: **DO NOT administer Leucovorin within 2 hours BEFORE or AFTER |
| Glucarpidase!** (Glucarpidase also hydrolyzes leucovorin, destroying both!). |
| - PHARMACY MANDATE 2: Continue Leucovorin therapy for at least 48 hours based on the |
| **PRE-glucarpidase MTX concentration**, because DAMPA cross-reacts on standard clinical |
| immunoassays, causing **falsely elevated MTX readings** for up to 48 hours! |
+---------------------------------------------------------------------------------------------------+
4. Uridine Triacetate (Vistogard) for Fluoropyrimidine Overdose
- Indication: Emergency treatment of adult and pediatric patients following an accidental overdose of 5-Fluorouracil (5-FU) or Capecitabine, OR patients exhibiting early, severe, life-threatening toxicities (severe mucositis, gastrointestinal toxicity, neutropenia, encephalopathy, or cardiotoxicity) within 96 hours of administration (including patients with unknown dihydropyrimidine dehydrogenase [DPYD] deficiency).
- Mechanism: Oral prodrug of uridine. Competitively dilutes and inhibits toxic fluorouridine triphosphate (FUTP) incorporation into cellular RNA, rescuing healthy host tissues.
- Dosing & Administration: 10 grams PO every 6 hours for 20 doses (total 5 days) in adults (6.2 g/m2/dose in pediatrics). Administer with food (mixed in applesauce or pudding). Must be initiated within 96 hours of 5-FU/capecitabine completion (overall survival >96% vs <16% in untreated historic controls).
5. Amifostine (Ethyol)
- Mechanism: Organic thiophosphate prodrug dephosphorylated by membrane-bound alkaline phosphatase (present in higher concentrations on normal vascular endothelium vs. malignant cells) into the active free thiol WR-1065, which scavenges reactive oxygen species and neutralizes reactive platinum species.
- Indications: (1) Reduction of cumulative cisplatin nephrotoxicity in advanced ovarian cancer or NSCLC; (2) Reduction of moderate-to-severe radiation-induced xerostomia in head and neck cancer.
- Adverse Effects & Interventions: Severe transient hypotension (infuse over 15 min with patient supine; hold antihypertensive medications for 24 hours prior) and severe emesis (mandates full 5-HT3 + dexamethasone antiemetic premedication).
6. Methylene Blue for Ifosfamide-Induced Neurotoxicity / Encephalopathy
- Pathophysiology: Ifosfamide undergoes side-chain dechloroethylation by hepatic CYP3A4/CYP2B6, yielding neurotoxic chloroacetaldehyde. Chloroacetaldehyde crosses the blood-brain barrier, depletes cerebral glutathione, and impairs mitochondrial respiratory chain complex I, causing encephalopathy, confusion, cerebellar ataxia, hallucinations, and coma.
- Pharmacotherapy: Discontinue ifosfamide immediately. Administer Methylene Blue 50 mg IV every 4 to 8 hours until resolution. Methylene blue acts as an alternative electron acceptor, bypassing blocked mitochondrial respiratory chain complex I and restoring oxidative phosphorylation. Co-administration of IV thiamine (100 mg) provides synergistic neuroprotection.
Test Your Knowledge
A 52-year-old female with metastatic breast cancer is receiving an intravenous infusion of doxorubicin via a peripheral IV catheter in her right forearm. Twenty minutes into the infusion, the patient complains of intense burning pain and swelling at the insertion site. The nurse immediately stops the infusion. Approximately 15 mL of doxorubicin solution is estimated to have extravasated, with visible perivascular swelling and induration. Which comprehensive management plan is most appropriate for this anthracycline extravasation?
A
B
C
D
Test Your Knowledge
A 28-year-old male with relapsed Hodgkin lymphoma receives vinblastine 6 mg/m2 IV push. Immediately following the injection, the nurse notes severe swelling, erythema, and localized pain around the peripheral IV site in the left wrist. How should the clinical oncology pharmacist guide the nursing and medical team to manage this vinca alkaloid extravasation?
A
B
C
D
Test Your Knowledge
A 21-year-old male with osteosarcoma receives High-Dose Methotrexate (12 g/m2 IV over 4 hours) with aggressive sodium bicarbonate hyperhydration (urine pH >= 7.5). At 48 hours post-infusion, his Serum Creatinine has spiked from 0.8 to 3.4 mg/dL with oliguria (urine output <20 mL/hr), and his 48-hour Serum Methotrexate level is critically elevated at 84 mcmol/L (well above the nomogram toxic threshold). The medical team orders Glucarpidase (Voraxaze) 50 units/kg IV push. What is the most critical pharmacokinetic and drug interaction pearl the oncology pharmacist must communicate regarding leucovorin administration?
A
B
C
D
Test Your Knowledge
A 42-year-old male with Ewing sarcoma is admitted to receive high-dose Ifosfamide (3 g/m2/day continuous IV infusion on Days 1 through 3; total 9 g/m2). Which organ protectant must be co-prescribed to prevent chemotherapy-induced hemorrhagic cystitis, and what is its pharmacological mechanism of action?
A
B
C
D